Early Cancer Detection Test, Ccheck, May Reduce Number of Unnecessary Prostate Biopsies, Anixa Says

Early Cancer Detection Test, Ccheck, May Reduce Number of Unnecessary Prostate Biopsies, Anixa Says
Ccheck, a new test for early cancer detection under development by Anixa Biosciences, was able to identify patients with aggressive prostate cancer, and helped decide who should be recommended for a prostate biopsy, potentially reducing the number of unnecessary biopsies, the company announced. The test may be also used for other cancer types in the future. The early findings are from an ongoing study validating Ccheck for prostate cancer screening and were presented at the 2019 American Association of Cancer Research Annual Meeting, held March 29–April 3 in Atlanta. The presentation, “Using machine learning to predict the risk of either having an aggressive form of prostate cancer (PCa) or lower-grade PCa/benign prostatic hyperplasia (BPH) based upon the flow cytometry immunophenotyping of
Subscribe or to access all post and page content.